TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma.

TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences, Inc. announced that the US FDA Office of Orphan Products Development has granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. [TuHURA Biosciences, Inc.] Press Release

FDA Grants Orphan Drug Status to IFx-2.0 for Advanced Melanoma Care

The FDA has granted orphan drug designation to IFx-2.0 for patients with stage 2B to stage 4 cutaneous melanoma.

Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma

IFx-2.0 showed a clinical benefit in an early phase 1 trial and has now been given orphan drug designation by the FDA for patients with stage IIB to IV cutaneous melanoma.